Provided by Tiger Fintech (Singapore) Pte. Ltd.

Mind Medicine (MindMed) Inc.

5.77
+0.31005.68%
Post-market: 5.75-0.0200-0.35%19:48 EDT
Volume:1.17M
Turnover:6.66M
Market Cap:434.88M
PE:-3.74
High:5.84
Open:5.46
Low:5.45
Close:5.46
Loading ...

Mind Medicine Doses First Patient in Phase 3 Trial on MM120 for Major Depressive Disorder

MT Newswires Live
·
15 Apr

BRIEF-Mindmed Announces First Patient Dosed In Phase 3 Emerge Study Of Mm120 In Major Depressive Disorder (Mdd)

Reuters
·
15 Apr

Mind Medicine (MindMed) Inc - Topline Data Expected in Second Half of 2026

THOMSON REUTERS
·
15 Apr

MindMed Announces First Patient Dosed in Phase 3 Emerge Study of Mm120 in Major Depressive Disorder (Mdd)

THOMSON REUTERS
·
15 Apr

MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD)

Business Wire
·
15 Apr

MindMed Announces New Employee Inducement Grants

Business Wire
·
25 Mar

Psychedelic: Exclusive talk with biotech company Clearmind Medicine

TipRanks
·
22 Mar

MindMed Appoints Matt Wiley as Chief Commercial Officer

THOMSON REUTERS
·
17 Mar

MindMed Appoints Matt Wiley as Chief Commercial Officer

Business Wire
·
17 Mar

Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial

TipRanks
·
14 Mar

Analysts Conflicted on These Healthcare Names: Mind Medicine (MNMD), RAPT Therapeutics (RAPT) and LifeMD (LFMD)

TIPRANKS
·
11 Mar

Mind Medicine’s (MNMD) Recent Achievements Boosting Stock

TIPRANKS
·
09 Mar

Mind Medicine Is Maintained at Outperform by Baird

Dow Jones
·
07 Mar

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Mind Medicine (MNMD), SurModics (SRDX) and Enhabit, Inc (EHAB)

TIPRANKS
·
07 Mar

Mind Medicine Price Target Maintained With a $55.00/Share by HC Wainwright & Co.

Dow Jones
·
07 Mar

Mind Medicine (MindMed) Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
06 Mar

Mind Medicine Q4 2024 GAAP EPS $(0.41) Misses $(0.30) Estimate, Cash And Cash Equivalents Of $273.7M As Of December 31, 2024, Expected To Fund Operations Into 2027 And Extend At Least 12 Months Beyond The First Phase 3 Topline Data Readout For MM120 Orally Disintegrating Tablet In Generalized Anxiety Disorder

Benzinga
·
06 Mar

BRIEF-MindMed FY Net Income USD -108.679 Million

Reuters
·
06 Mar

MindMed FY Basic EPS USD -1.54

THOMSON REUTERS
·
06 Mar

MindMed FY Operating Expenses USD 103.916 Million

THOMSON REUTERS
·
06 Mar